Literature DB >> 19630773

Structural and functional features of factor XI.

D Gailani1, S B Smith.   

Abstract

Factor XI (FXI) has structural and mechanistic features that distinguish it from other coagulation proteases. A relatively recent addition to vertebrate plasma coagulation, FXI is a homodimer, with each subunit containing four apple domains and a protease domain. The apple domains form a disk structure with binding sites for platelets, high molecular weight kininogen, and the substrate factor IX (FIX). FXI is converted to the active protease FXIa by cleavage of the Arg369-Ile370 bond on each subunit. This converts the catalytic domains to the active forms, and unmasks exosites on the apple domains required for FIX binding. FXI activation by factor XIIa or thrombin proceeds through an intermediate with only one activated submit (1/2-FXIa). 1/2-FXIa activates FIX in a similar manner to FXIa. While the importance of the homodimeric structure of FXI is not certain, it may represent a strategy for binding to FIX and a platelet surface simultaneously.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19630773      PMCID: PMC2849299          DOI: 10.1111/j.1538-7836.2009.03414.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  13 in total

1.  Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX.

Authors:  M F Sun; M Zhao; D Gailani
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

2.  Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein.

Authors:  Thomas Renné; David Gailani; Joost C M Meijers; Werner Müller-Esterl
Journal:  J Biol Chem       Date:  2001-11-30       Impact factor: 5.157

3.  Crystal structure of the factor XI zymogen reveals a pathway for transactivation.

Authors:  Evangelos Papagrigoriou; Paul A McEwan; Peter N Walsh; Jonas Emsley
Journal:  Nat Struct Mol Biol       Date:  2006-05-14       Impact factor: 15.369

4.  Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation.

Authors:  Dharmaraj Samuel; Hong Cheng; Paul W Riley; Adrian A Canutescu; Chandrasekaran Nagaswami; John W Weisel; Zimei Bu; Peter N Walsh; Heinrich Roder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-20       Impact factor: 11.205

Review 5.  Factor XI in haemostasis and thrombosis: past, present and future.

Authors:  Uri Seligsohn
Journal:  Thromb Haemost       Date:  2007-07       Impact factor: 5.249

6.  Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa.

Authors:  Wenman Wu; Dipali Sinha; Sergei Shikov; Calvin K Yip; Thomas Walz; Paul C Billings; James D Lear; Peter N Walsh
Journal:  J Biol Chem       Date:  2008-04-25       Impact factor: 5.157

7.  Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation.

Authors:  E Hooley; P A McEwan; J Emsley
Journal:  J Thromb Haemost       Date:  2007-10-08       Impact factor: 5.824

8.  Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI.

Authors:  Frank A Baglia; David Gailani; José A López; Peter N Walsh
Journal:  J Biol Chem       Date:  2004-08-17       Impact factor: 5.157

Review 9.  Update on the physiology and pathology of factor IX activation by factor XIa.

Authors:  Stephen B Smith; David Gailani
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

10.  Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation.

Authors:  Stephen B Smith; Ingrid M Verhamme; Mao-fu Sun; Paul E Bock; David Gailani
Journal:  J Biol Chem       Date:  2008-01-11       Impact factor: 5.157

View more
  21 in total

1.  Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.

Authors:  Rami A Al-Horani; David Gailani; Umesh R Desai
Journal:  Thromb Res       Date:  2015-04-22       Impact factor: 3.944

Review 2.  Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).

Authors:  Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2019-12-19       Impact factor: 6.674

Review 3.  Structure and function of factor XI.

Authors:  Jonas Emsley; Paul A McEwan; David Gailani
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

4.  High-resolution crystal structures of factor XIa coagulation factor in complex with nonbasic high-affinity synthetic inhibitors.

Authors:  Xavier Fradera; Bert Kazemier; Emma Carswell; Andrew Cooke; Arthur Oubrie; William Hamilton; Maureen Dempster; Stephan Krapp; Susanna Nagel; Anja Jestel
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-03-27

5.  A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.

Authors:  Rami A Al-Horani; Elsamani I Abdelfadiel; Daniel K Afosah; Shravan Morla; Jyothi C Sistla; Bassem Mohammed; Erika J Martin; Masahiro Sakagami; Donald F Brophy; Umesh R Desai
Journal:  J Thromb Haemost       Date:  2019-09-10       Impact factor: 5.824

6.  Polyphosphate is a cofactor for the activation of factor XI by thrombin.

Authors:  Sharon H Choi; Stephanie A Smith; James H Morrissey
Journal:  Blood       Date:  2011-10-05       Impact factor: 22.113

Review 7.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 8.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

Review 9.  Factor XIa inhibitors: A review of the patent literature.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Expert Opin Ther Pat       Date:  2016       Impact factor: 6.674

10.  The Eph tyrosine kinase receptors EphB2 and EphA2 are novel proteolytic substrates of tissue factor/coagulation factor VIIa.

Authors:  Oskar Eriksson; Margareta Ramström; Katarina Hörnaeus; Jonas Bergquist; Dariush Mokhtari; Agneta Siegbahn
Journal:  J Biol Chem       Date:  2014-10-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.